10:30 AM EST, 11/05/2025 (MT Newswires) -- Arch Biopartners ( ACHFF ) announced Wednesday that the Fraser Health Research Ethics Board granted approval for the Royal Columbian Hospital (RCH) to participate in the company's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

The company said the clinical team at RCH in New Westminster, British Columbia, will proceed to complete operational approvals, training, and site initiation prior to starting patient enrollment. It said it continues to evaluate additional sites in Canada and the U.S. to join the CS-AKI Phase II trial.

Arch Biopartners ( ACHFF ) also said that the TSX Venture Exchange granted final approval for its acquisition of Lipdro Therapeutics, details of which were announced in September.

Shares of the company were last seen up about 1% at $1.04 on the TSXV.

Price: 1.04, Change: +0.01, Percent Change: +0.97